Dr. Seidah discovered and cloned seven (PC1, PC2, Furin, PC4, PC5, PACE4, PC7, SKI-1 and PCSK9) of the nine known secretory serine proteases belonging to the proprotein convertases family. During this period, he also greatly contributed to demonstrating that proteolysis by the proprotein convertases is a widely used mechanism that also affects “non-neuropeptide” proteins such as growth factors, α-integrins, receptors, enzymes, membrane-bound transcription factors, and bacterial and viral proteins. In 2003, he identified PCSK9 and showed that point mutations in the PCSK9 gene cause dominant familial hypercholesterolemia, since PCSK9 gain-of-function mutations were linked to the ability of PCSK9 to enhance the degradation of cell surface receptors, such as the low-density lipoprotein receptor (LDLR). Dr Seidah has since worked on the elucidation of the functions and mechanisms of action of PCSK9 both in cells and in vivo, and is developing specific PCSK9 inhibitors.
Over the last 44 years, Dr. Seidah has attracted more than 146 graduate students, trainees and post-doctoral fellows. He is a member of numerous scientific associations including the Cancer Research Society and the American Heart Association. In 1991, he was elected fellow of the Royal Society of Canada. Dr Seidah is the recipient of several awards, including the 1995 Medical Research Council Scientist Award, he has been a member of the Order of Quebec since 1997 and of the Order of Canada since 1999. In 2001, he received the McLaughlin Medal of the Royal Society of Canada and the Parizeau Prize of the Association Canadienne-Française pour l'Avancement des Sciences (ACFAS). Since 2003 Dr Seidah has been endowed with a Tier-1 Canada chair on “Precursor Proteolysis”. In 2009 he received the Pfizer Distinguished Cardiovascular-Metabolic Research Jean-Davignon Award. In 2011, he was awarded the Wilder Penfield prize for the best scientist in Québec working in the biomedical field. In 2013, he was awarded the Queen Elizabeth II Diamond Jubilee Medal. In 2014, he received in Winnipeg the “Jacques Genest” Lecturer Award from the Canadian Society of Endocrinolgy and Metabolism. In 2016, he was selected as the recipient of the annual CIHR-ICRH Distinguished Lecturer Award in Cardiovascular Sciences in Canada. In 2018, he was selected for the prestigious Akira Endo Award for his seminal contributions to PCSK9 that led to a new powerful treatment for atherosclerosis, and was also granted the major Lefoulon Delalande award of the Institut de France for Research & Innovation in cardiovascular disease, as well as the 2018 McGill University Louis & Artur Lucian award for research in circulatory diseases. On August 12, 2018 Dr Seidah was selected by La Presse de Montréal as the personality of the week.
He has been invited as a speaker nationally and internationally to give more than 450 presentations, and over the years Dr Seidah gave more than 20 plenary lectures worldwide. In 1995, he organized the first Keystone conference on proprotein convertases. In 2006 he was the chairman of a prestigious Gordon Research Conference on "Proprotein Processing, Trafficking and Secretion" (Colby Sawyer College, NH, USA). In 2013 he was invited to present the “Simon Pierre-Noël Memorial Lecture” at the Canadian Lipoprotein Conference in Mont-Tremblant, Québec, Canada. In 2018 and 2019, he delivered keynote lectures for the “Akira Endo” and “Louis & Artur Lucian” awards on the discovery and clinical applications of PCSK9.
Dr Seidah is internationally recognized as a world leader in convertases and their physiological roles. His numerous publications that tally more than 740 peer reviewed manuscripts have been widely recognized, and in fact he is cited as the most recognized protease expert in Canada and 6th worldwide. Indeed, Pubmed cites N.G. Seidah as the topmost in Canada and the 1st out of the worldwide 20 top scientists working on “Proprotein Convertases” since 1971. His H index = 95 (Web of Science), and his work has been cited more than 35,000 times.